Cargando…

In need of new drugs: Forgetting current use of the available drugs for tuberculosis

Detalles Bibliográficos
Autores principales:	Mukhida, Sahjid S., Vyawhare, Chanda, Das, Pankaj, Das, Nikunja Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2023
Materias:	Research Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298823/ https://www.ncbi.nlm.nih.gov/pubmed/37148032 http://dx.doi.org/10.4103/lungindia.lungindia_23_23

Ejemplares similares

When should we be able to divert the cost of tuberculosis to other diseases?
por: Mukhida, Sahjid S., et al.
Publicado: (2023)

What are the hurdles in the pathway of COVID-19 convalescent plasma collection in low-income nations?
por: Mukhida, Sahjid, et al.
Publicado: (2023)

Should we have to submit a letter to editor only in those journals which previously published our letter?
por: Mukhida, Sahjid S., et al.
Publicado: (2023)

What is actual condition of working parents about child nurturing and what they have to do?
por: Mukhida, Sahjid S., et al.
Publicado: (2023)

Who required the counselling to stop intimate partner violence, victim or perpetrators?
por: Mukhida, Sahjid S., et al.
Publicado: (2023)

Does India’s Zero by 30 Strategic Plan Need the Addition of the Rabies Vaccine to the Universal Immunisation Programme?
por: Mukhida, Sahjid, et al.
Publicado: (2023)

Drones for Medical Supply During Disaster: A Game Changer in “Health for All” Policy
por: Das, Nikunja Kumar, et al.
Publicado: (2023)

Introduction of Diphtheria Component Addition in Immunization During Pregnancy
por: Mukhida, Sahjid, et al.
Publicado: (2023)

Diagnosis and treatment of latent tuberculosis infections in high burden settings: A Herculean task
por: Vyawahare, Chanda, et al.
Publicado: (2023)

Reply to the syndemic of “COVID-19 and tuberculosis”
por: Patil, Rajashri A., et al.
Publicado: (2023)

A case series and literature review of infections due to Myroides spp.: identification of contributing factors and emerging antibiotic susceptibility trends
por: Khan, Uzair, et al.
Publicado: (2023)

Can health insurance help to improve the personal and economical health of India?
por: Mukhida, Sahjid S., et al.
Publicado: (2023)

How precautionary medicine and public health are attached?
por: Mukhida, Sahjid, et al.
Publicado: (2023)

The syndemic of “COVID-19 and tuberculosis”
por: Das, Nikunja K., et al.
Publicado: (2022)

Role of GeneXpert MTB/RIF assay for the diagnosis of cervical lymph node tuberculosis and rifampicin resistance
por: Mukhida, Sahjid, et al.
Publicado: (2022)

Reply to Role and importance of journal reader: Scientific contribution of letter to editor
por: Das, Nikunja K., et al.
Publicado: (2023)

Pakistan floods: Many lesson for all nations
por: Das, Nikunja K., et al.
Publicado: (2023)

Impact of the COVID-19 pandemic on tuberculosis in Peru: Are we forgetting anyone?()
por: Cardenas-Escalante, Jhanella, et al.
Publicado: (2022)

The Current Status of New Antidiabetic Drugs
por: Pemminati, Sudhakar, et al.
Publicado: (2016)

Are we forgetting the “universal” in universal masking? Current challenges and future solutions
por: Advani, Sonali D., et al.
Publicado: (2020)

Herd immunity: Deadly or defensive
por: Khan, Sameena, et al.
Publicado: (2021)

Don’t forget the bladder!
por: Oosterveld, Bernard J., et al.
Publicado: (2018)

Don’t Forget Dengue!
por: Nyamugunduru, G
Publicado: (1998)

New insights into the use of currently available non-steroidal anti-inflammatory drugs
por: Brune, Kay, et al.
Publicado: (2015)

Needle Stick Injury From a COVID-19 Patient—Fear It or Forget It?
por: Keri, Vishakh C., et al.
Publicado: (2021)

Rhino-orbital cerebral mycosis: a case series of non-mucorales in COVID patients
por: Patil, Rajashri, et al.
Publicado: (2023)

SARS-CoV-2 vaccine breakthrough infection following a previous infection in a healthcare worker
por: Gupta, Aayush, et al.
Publicado: (2022)

Currently available drugs for the treatment of Coronavirus-2
por: Anbarasan, T., et al.
Publicado: (2022)

Drug-Resistant Mycobacterium tuberculosis among New Tuberculosis Patients, Yangon, Myanmar
por: Phyu, Sabai, et al.
Publicado: (2003)

When comparing the safety of drugs, don't forget the exposure dimension
por: Zoccali, Carmine
Publicado: (2023)

The need to accelerate access to new drugs for multidrug-resistant tuberculosis
por: Cox, Helen S, et al.
Publicado: (2015)

Acanthoma Fissuratum: Lest we Forget
por: Deshpande, Nikhil S., et al.
Publicado: (2017)

A totally new system is needed for drug research and development
por: Gøtzsche, Peter C.
Publicado: (2018)

Inflammatory pseudotumor of urinary bladder: Beware lest we forget
por: Garg, Pankaj Kumar
Publicado: (2014)

Epilepsy Care- Awarness, Cost and Availability of Antiepileptic Drugs
por: Shubhakaran, Khichar
Publicado: (2021)

Limited Capability for Testing Mycobacterium tuberculosis for Susceptibility to New Drugs
por: Farooq, Hamzah Z., et al.
Publicado: (2021)

Pyridoxine Trial in Early Infantile Epileptic Encephalopathy: Never Forget!
por: Sharawat, Indar Kumar, et al.
Publicado: (2020)

Outcomes associated with standardized treatment regimens for extensively drug-resistant tuberculosis
por: Aggarwal, Anivita, et al.
Publicado: (2020)

Resistance to Artemisinin Combination Therapies (ACTs): Do Not Forget the Partner Drug!
por: Nsanzabana, Christian
Publicado: (2019)

COVID-19 and the burning issue of drug interaction: never forget the ECG
por: Sciaccaluga, Carlotta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tm7um9f2thd0cgttgagsn1ikcc